• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

局部光化性角化病治疗应用的国际时间趋势及差异

International time trends and differences in topical actinic keratosis therapy utilization.

作者信息

Zhao Heather J, Ushcatz Inna, Tadrous Mina, Aoki Valeria, Chang Aileen Y, Levell Nick J, Von Schuckmann Lena, Drucker Aaron M

机构信息

Department of Medicine, Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.

Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

JAAD Int. 2024 Apr 2;16:18-25. doi: 10.1016/j.jdin.2024.03.013. eCollection 2024 Sep.

DOI:10.1016/j.jdin.2024.03.013
PMID:38764482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11099316/
Abstract

BACKGROUND

Actinic Keratoses (AK) are precancerous lesions that can lead to Squamous Cell Carcinoma. International differences in the utilization of topical medications to treat AK are not well described.

OBJECTIVES

To describe international differences in topical AK medication utilization, including associations of countries' economic status with AK medication utilization.

METHODS

We used IQVIA MIDAS pharmaceutical sales data for 65 countries (42 high-income, 24 middle-income) from April 2011 to December 2021. We calculated each country's quarterly utilization of medications in grams per 1000 population. We used univariable linear regression to assess the association between country economic status and AK medication utilization.

RESULTS

High-income countries used 15.37 more grams per 1000 population of 5-fluorouracil (95% CI: 9.68, 21.05), 4.64 more grams per 1000 population of imiquimod (95% CI: 3.45, 5.83), and 0.32 more grams per 1000 population of ingenol mebutate (95% CI: 0.05, 0.60).

LIMITATIONS

Missing medication utilization data for some countries.

CONCLUSION

High-income countries use more topical AK therapies than middle-income countries.

摘要

背景

光化性角化病（AK）是可导致鳞状细胞癌的癌前病变。关于治疗AK的局部用药使用情况的国际差异尚无详尽描述。

目的

描述局部AK用药使用情况的国际差异，包括各国经济状况与AK用药使用情况的关联。

方法

我们使用了艾昆纬MIDAS从2011年4月至2021年12月期间65个国家（42个高收入国家、24个中等收入国家）的药品销售数据。我们计算了每个国家每1000人口的季度用药使用量（以克为单位）。我们使用单变量线性回归来评估国家经济状况与AK用药使用情况之间的关联。

结果

高收入国家每1000人口使用5-氟尿嘧啶的量多出15.37克（95%置信区间：9.68，21.05），每1000人口使用咪喹莫特的量多出4.64克（95%置信区间：3.45，5.83），每1000人口使用鬼臼毒素的量多出0.32克（95%置信区间：0.05，0.60）。

局限性

部分国家缺少用药使用数据。

结论

高收入国家比中等收入国家使用更多的局部AK治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09eb/11099316/1d945a482aa2/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09eb/11099316/62672fc67c47/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09eb/11099316/1d945a482aa2/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09eb/11099316/62672fc67c47/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09eb/11099316/1d945a482aa2/gr1a.jpg

相似文献

1
International time trends and differences in topical actinic keratosis therapy utilization.局部光化性角化病治疗应用的国际时间趋势及差异
JAAD Int. 2024 Apr 2;16:18-25. doi: 10.1016/j.jdin.2024.03.013. eCollection 2024 Sep.
2
Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).一项针对美国食品药品监督管理局不良事件报告系统（FAERS）的药物警戒研究表明，光化性角化病患者使用鬼臼毒素丁酯后，鳞状细胞癌的报告几率增加。
J Cutan Med Surg. 2023 Jan-Feb;27(1):39-43. doi: 10.1177/12034754221143091. Epub 2022 Dec 10.
3
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.在荷兰进行的一项基于试验的成本效益分析，比较了局部使用5-氟尿嘧啶、咪喹莫特、鬼臼毒素和甲基氨基乙酰丙酸传统光动力疗法治疗头颈部光化性角化病的效果。
Br J Dermatol. 2020 Oct;183(4):738-744. doi: 10.1111/bjd.18884. Epub 2020 Feb 19.
4
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).器官移植受者光化性角化病的局部治疗：SPOT（使用局部治疗预防器官移植受者鳞状细胞癌）的可行性研究。
Br J Dermatol. 2022 Sep;187(3):324-337. doi: 10.1111/bjd.20974. Epub 2022 Jun 14.
5
Interventions for actinic keratoses.光化性角化病的干预措施。
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD004415. doi: 10.1002/14651858.CD004415.pub2.
6
Association of Countries' Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization.
Dermatitis. 2025 Mar-Apr;36(2):133-140. doi: 10.1089/derm.2024.0107. Epub 2024 Jul 3.
7
Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.英诺皮肤活化剂治疗光化性角化病的药代动力学和药效学评价。
Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):911-918. doi: 10.1080/17425255.2018.1508449. Epub 2018 Aug 9.
8
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.咪喹莫特凝胶治疗光化性角化病的成本效用分析：苏格兰视角
Eur J Health Econ. 2016 Apr;17(3):287-304. doi: 10.1007/s10198-015-0679-8. Epub 2015 Mar 21.
9
Ingenol mebutate: A novel topical drug for actinic keratosis.鬼臼毒素：一种治疗光化性角化病的新型外用药物。
Indian Dermatol Online J. 2013 Jul;4(3):246-9. doi: 10.4103/2229-5178.115538.
10
Pharmacoeconomic evaluations in the treatment of actinic keratoses.光化性角化病治疗的药物经济学评价。
Int J Immunopathol Pharmacol. 2017 Jun;30(2):178-181. doi: 10.1177/0394632017697719. Epub 2017 Mar 1.

本文引用的文献

1
The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990-2017.皮肤癌的全球负担：来自1990 - 2017年全球疾病负担研究的纵向分析。
JAAD Int. 2021 Jan 4;2:98-108. doi: 10.1016/j.jdin.2020.10.013. eCollection 2021 Mar.
2
Guidelines of care for the management of actinic keratosis.光化性角化病治疗管理指南。
J Am Acad Dermatol. 2021 Oct;85(4):e209-e233. doi: 10.1016/j.jaad.2021.02.082. Epub 2021 Apr 2.
3
Impact of the COVID-19 Pandemic on Dermatology Practice Worldwide: Results of a Survey Promoted by the International Dermoscopy Society (IDS).
2019年冠状病毒病疫情对全球皮肤科实践的影响：国际皮肤镜检查学会（IDS）发起的一项调查结果
Dermatol Pract Concept. 2021 Jan 29;11(1):e2021153. doi: 10.5826/dpc.1101a153. eCollection 2021 Jan.
4
Impacts of COVID-19 on Dermatologic Practice, Disease Presentation, and Immunomodulator Prescriptions.2019年冠状病毒病对皮肤科诊疗、疾病表现及免疫调节剂处方的影响。
J Cutan Med Surg. 2021 Jan-Feb;25(1):106-108. doi: 10.1177/1203475420960437. Epub 2020 Sep 16.
5
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.在荷兰进行的一项基于试验的成本效益分析，比较了局部使用5-氟尿嘧啶、咪喹莫特、鬼臼毒素和甲基氨基乙酰丙酸传统光动力疗法治疗头颈部光化性角化病的效果。
Br J Dermatol. 2020 Oct;183(4):738-744. doi: 10.1111/bjd.18884. Epub 2020 Feb 19.
6
Randomized Trial of Four Treatment Approaches for Actinic Keratosis.随机对照临床试验：四种光化性角化病治疗方法的比较
N Engl J Med. 2019 Mar 7;380(10):935-946. doi: 10.1056/NEJMoa1811850.
7
Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: A network meta-analysis.在光化性角化病患者中，5-氟尿嘧啶与其他治疗方法的相对疗效：一项网状荟萃分析。
Dermatol Ther. 2019 May;32(3):e12822. doi: 10.1111/dth.12822. Epub 2019 Feb 14.
8
Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.比较外用氟尿嘧啶和咪喹莫特治疗光化性角化病预防角质形成细胞癌的疗效：一项队列研究。
J Am Acad Dermatol. 2019 Apr;80(4):998-1005. doi: 10.1016/j.jaad.2018.11.024. Epub 2018 Nov 17.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
United States Food and Drug Administration Product Label Changes.美国食品药品监督管理局产品标签变更
J Clin Aesthet Dermatol. 2017 Feb;10(2):20-29. Epub 2017 Feb 1.